The government tries to tighten the production of the vaccine in Italy. And the number one candidate is the M-Rna serum produced by the Modern American with which the “negotiation is well under way”, the Ministry of Economic Development reported. Where those who follow the dossier say they are confident that they will be able to close an agreement as early as September, the first stage for the production of serums which, however, would only see the light from 2022.
From Moderna for now “no comment”, but the path could be the one already followed with the Canadian government with which the company signed a memorandum of understanding on 10 August for the construction of a state-of-the-art factory for production of its vaccines. In pole position, for an agreement of this type, is the Catalent of Anagni, which should supply its factories. The dossier is therefore in an advanced state but it has not yet been clarified whether the investment will be “greenfield” – therefore with the creation of a new production activity – or will focus on the reconversion of plants that are already operational.
Loading…
To weigh on this choice will also be the incentives for vaccine production just fired by the Mise in the Sostegni bis decree in force since last July 25: ranging from the tax credit on research on drugs and vaccines of 20% (for a maximum annual ceiling of 20 million) to the incentives that the newly founded Enea Tech Foundation will manage and Biomedical, which is still waiting for the new Statute, while a possible board of directors begins to take shape.
Three members belong to the Mise, one to the Miur and one to the Ministry of Health. The president, in quota Mise, should be the former minister of the economy Giovanni Tria. It is possible that the immunologist Sergio Abrignani, a member of the Technical Scientific Committee, also joins the council, at the Miur share. And Giorgio Palù, president of Aifa, in quota Mise could also make his entry into the newborn foundation.
Enea Tech and Biomedical it started last year with an initial dowry of 500 million, to be used for start-ups in various sectors, when the biomedical segment had not yet been added. At the beginning of the summer, the definition “biomedical” was added, with an additional 400 million, with the aim of using a total of 650 million for the biomedical sector (and therefore, it can be assumed, precisely for the anti-Covid vaccine supply chain). The initial core business, focused on start-ups, has therefore changed and the dossiers started by Invitalia could also be included.
–
